By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Karolchyk, John Scott (Lake Hopatcong, NJ); Saadeh, Dennis Elias (Irvine, CA), filed on January 5, 2017, was made available online on May 4, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents (see also Patents).
This patent application has not been assigned to a company or institution.
The following quote was obtained by the news editors from the background information supplied by the inventors: "In ophthalmological treatments and procedures, many typical ophthalmic drug delivery systems encounter difficulties and problems due to physiological conditions of the eye. More specifically, when a liquid ophthalmic formulation is applied to the eye, upon instillation, it is quickly eliminated due to lacrimal secretion and drainage. As a result, only a limited number of ophthalmic drugs can be utilized by patients to achieve efficient treatment; otherwise a frequent administration of concentrated solutions is often required to achieve the desired effects. It naturally follows that increasing the retention time of a liquid ophthalmic formulation after it has been administered is often very desirable. Similarly, the same is desirable for topical drug formulations that are applied to the skin of burn patients to relieve burn symptoms and to accelerate the process of healing or to gun-shot victims to seal a wound and prevent loss of blood.
"In the field of ophthalmology, to lengthen the retention time of an instilled drug in the eye and to enhance its bioavailability, various ophthalmic vehicles, such as ointments, aqueous gels, suspensions inserts and implants, have been developed and used. However, these ophthalmic vehicles are not free of flaws and drawbacks. For example, the use of ointments often causes blurred vision. Using inserts causes serious problems due to low patient compliance. Implants require surgical intervention with concomitant risks of infection and inflammation.
"Gel forming systems have been especially popular for increasing the pre-corneal retention time and improving bioavailability of the ophthalmic drugs. Typically, such gels comprise thermoreversible polymers that can undergo a rapid liquid-to-gel phase transition once they have been administered to the eye. However, typical in situ gel-forming compositions require the use of high concentrations of polymer to form the gel and therefore typically are not suitable for use in ophthalmic drug delivery.
"This patent specification discloses alternative in situ gel-forming compositions that are free of the above-described drawbacks and deficiencies making them better suited for both ophthalmological and burn-healing treatments. Also, methods of fabricating and administering the same are provided herein."
In addition to the background information obtained for this patent application, NewsRx journalists also obtained the inventors' summary information for this patent application: "According to one embodiment of the invention, a pharmaceutical ophthalmological composition or a composition for treating dry eye syndrome is provided, the composition comprising a therapeutically effective quantity of an active component that is free of any of fluconazole, methazolamide, azitromycin, mitomycin, pilocarpine, povidone-iodine, dexamethasone, flurbiprofen, bromfenac, nepafenac, diclofenac, ketorolac, indomethacin, suprofen, norfloxacin, ciprofloxacin, antiseptics comprising the NH.sub.4.sup.+ cation or pharmaceutically acceptable isomers, salts, hydrates or solvates thereof; and a quantity of a thermoreversible gel component that is free of any of chitosan, carbopol or polysorbate.
"According to another embodiment of the invention, the active component of the pharmaceutical ophthalmological composition comprises at least one anesthetic, at least one non-steroid anti-inflammatory drug (NSAID), at least one anti-bacterial agent, at least one antiviral medicament, at least one antifungal medicament, at least one immunosuppressant, at least one corticosteroid, at least one keratopathy agent, at least one antioxidant, at least one vitamin, at least one medicament for treating glaucoma, at least one mydriatic agent, at least one antihistamine agent, at least one anti-VEGF medicament, at least one medicament for corneal pain treatment or at least one medicament for dry eye syndrome treatment.
"According to other embodiments of the invention, an ophthalmological pharmaceutical composition is provided, the composition comprising a therapeutically effective quantity of an corticosteroid selected from the group consisting of triamcinolone, dexamethasone, betamethasone, fluorometholone, fluocinolone, prednisone, prednisolone, hydrocortisone and combinations thereof; a therapeutically effective quantity of an anti-bacterial agent selected from the group consisting of moxifloxacin, gatifloxacin, nalidixic acid, oxolinic acid, piromidic acid, pipemidic acid, rosoxacin, enoxacin, fleroxacin, lomefloxacin, nadifloxacin, ofloxacin, pefloxacin, rufloxacin, balofloxacin, levofloxacin, pazufloxacin, sparfloxacin, tosufloxacin, clinafloxacin, gemifloxacin, sitafloxacin, prulifloxacin and combinations thereof; and a quantity of a thermoreversible gel component comprising a polymer selected from the group consisting of poly(oxyethlene-co-oxypropylene) block copolymer, poly(N-isopropylacrylamide), poly(N-isopropylacrylamide-co-acrylic acid), poly(vinyl pyrrolidone), poly(4-vinylpyridine-co-ethylacrylate) block copolymer, poly(N-isopropylacrylamide-co-butyl methacrylate-co-ethylene glycol) block copolymer and combinations thereof.
"According to yet another embodiment of the invention, the active component of the pharmaceutical composition for treating burns comprises at least one anesthetic, at least one non-steroid anti-inflammatory drug, at least one anti-bacterial agent, at least one antifungal medicament, at least one burn-healing agent or at least one medicament for treating neuropathic pain.
"Examples of suitable specific active components as well as concentrations thereof are further provided herein, for both ophthalmological compositions and compositions for treating burns.
"According to another embodiment of the invention, the gel component of pharmaceutical compositions described herein includes thermoreversible polymer(s), for example, poly(oxyethlene-co-oxypropylene) block copolymer, such as Poloxamer 407.RTM., including thermoreversible polymers having cross-linked portion(s).
"According to yet another embodiment of the invention, the gel component of pharmaceutical compositions described herein is sterile, and methods of sterilization of the gel component are also provided herein.
"According to other embodiment of the invention, methods of preparing and using the pharmaceutical compositions described herein are also described herein."
URL and more information on this patent application, see: Karolchyk, John Scott; Saadeh, Dennis Elias. Pharmaceutical Compositions Comprising Gels and Methods for Fabricating Thereof. Filed January 5, 2017 and posted May 4, 2017. Patent URL: http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220170112936%22.PGNR.&OS=DN/20170112936&RS=DN/20170112936
Keywords for this news article include: Patents, Bacterial Infections and Mycoses.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC